Somatic mutations and germline sequence variants in the expressed tyrosine kinase genes of patients with de novo acute myeloid leukemia
Michael H. Tomasson, Zhifu Xiang, Richard A. Walgren et al. · Blood · 2008
Activating mutations in tyrosine kinase (TK) genes (eg, FLT3 and KIT) are found in more than 30% of patients with de novo acute myeloid leukemia (AML); many groups have speculated that mutations in other TK genes may be present in the remaining 70%. We performed high-throughput resequencing of the kinase domains of 26 TK genes (11 receptor TK; 15 cytoplasmic TK) expressed in most AML patients using genomic DNA from the bone marrow (tumor) and matched skin biopsy samples ("germline") from 94 patients with de novo AML; sequence variants were validated in an additional 94 AML tumor samples (14.3 million base pairs of sequence were obtained and analyzed). We identified known somatic mutations in FLT3, KIT, and JAK2 TK genes at the expected frequencies and found 4 novel somatic mutations, JAK1(V623A), JAK1(T478S), DDR1(A803V), and NTRK1(S677N), once each in 4 respective patients of 188 tested. We also identified novel germline sequence changes encoding amino acid substitutions (ie, nonsynonymous changes) in 14 TK genes, including TYK2, which had the largest number of nonsynonymous sequence variants (11 total detected). Additional studies will be required to define the roles that these somatic and germline TK gene variants play in AML pathogenesis.
Cited by 227 works. doi:10.1182/blood-2007-09-113027 Open-access PDF
Authors
- Michael H. Tomasson
- Zhifu Xiang
- Richard A. Walgren
- Yu Zhao
- Yumi Kasai
- Tracie L. Miner
- Rhonda E. Ries
- Olga Lubman
- Daved H. Fremont
- Michael D. McLellan
- Jacqueline E. Payton
- Peter Westervelt
- John F. DiPersio
- Daniel C. Link
- Matthew J. Walter
- Timothy Aaron Graubert
- Mark A. Watson
- Jack Baty
- Sharon E. Heath
- William D. Shannon
References
- Use of Chemotherapy plus a Monoclonal Antibody against HER2 for Metastatic Breast Cancer That Overexpresses HER2
- Efficacy and Safety of a Specific Inhibitor of the BCR-ABL Tyrosine Kinase in Chronic Myeloid Leukemia
- The Consensus Coding Sequences of Human Breast and Colorectal Cancers
- Patterns of somatic mutation in human cancer genomes
- A unique clonal JAK2 mutation leading to constitutive signalling causes polycythaemia vera
- A Gain-of-Function Mutation of JAK2 in Myeloproliferative Disorders
- Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders
- Fusion of a Kinase Gene, ALK , to a Nucleolar Protein Gene, NPM , in Non-Hodgkin's Lymphoma
- Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis
- Mutational Analysis of the Tyrosine Kinome in Colorectal Cancers